Heart Disease Outcomes: Impact of Genetics and Pharmacogenetics (INVEST Sub-study) – 1998
An Open, Randomized, Parallel-Group, Multicenter Trial to Compare a Stratified Care Treatment Regimen based on Migraine Disability (MIDAS grade) versus Standard Therapy for the Acute Treatment of Migraine Headache – 2000
Randomized, Open Label, Multicenter Trial of the Safety and Effectiveness of Oral Telithromycin (Ketekâ) and Amoxicillin/Clavulanic Acid (Augmentinâ) in Outpatients with Respiratory Infections in Usual Care Settings – 2000
A Multicenter, Randomized, Open-label Comparison of the Effects of ZOMIG-ZMTÔ (zolmitriptan) and Usual Migraine Care on Work Loss, Productivity, and Patient Preference – 2001
Glycemia Optimization Treatment (GOT): To Assess the Safety of Glucose Control as measured by the Frequency of Severe Hypoglycemia Events Using Dosing Algorithms Based on Different Fasting Blood Glucose Goals with Lantus (Insulin Glargine [rDNA Origin] in Adult Individuals with Type 2 Diabetes Who Have Not Achieved the Target A1c Goal of <7% with Oral Hypoglycemia Agents: A Randomized, Open-Label, Parallel-Design Trial – 2002
Impact of Point-of-Care vs. Laboratory Testing of Hemoglobin A1c (HbA1c) and Intense vs. Standard Monitoring of Titration Algorithm Adherence on Glycemic Control in Type 2 Diabetes Subjects, Who Are Inadequately Controlled on Oral Anti-Hyperglycemic Therapy, and Starting Lantusâ (Insulin Glargine [rDNA origin] Injection): A 2X2, Randomized, Open-Label Trial – 2002